Jiangchuan Macrolide Facility Update

CHENGDU, China, July 16 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics provides progress update on its Jiangchuan macrolide facility.

The construction of the facility is on schedule, targeting August for completion and equipment installation, immediately followed by GMP certification and trial production. The state-of-the-art macrolide facility, occupying 100mu (~16.5 acres) of land at Sichuan Xinjin Industrial Park near Chengdu, is designed for a total annual capacity of 240 tons of macrolide Active Pharmaceutical Ingredients (API) to serve the growing macrolide antibiotics market.

Jiangchuan macrolide initiative, established in 2009, is designed for the research and development, manufacturing and sales & marketing of API and chemical intermediates of macrolide antibiotics for Azithromycin, Clarithromycin, and Roxithromycin.

Dr. Jiang Guoqing, CEO of Tianyin Pharmaceutical pointed out, "Jiangchuan macrolide initiative expands our scope of business into the large arena of antibiotics. Jiangchuan is not only of great strategic significance and sustainable economic benefits, but also projected to become a leading manufacturer of macrolide antibiotics in China. It captures the growth momentum created by the ongoing healthcare reform. The steady increase of the macrolide raw material prices reaffirmed our market forecast. Additionally, the API business has an efficient profit chain that consists of three key elements: 1) raw material processing, 2) API production, and 3) sales, which are favorable for its healthy cash flow and resilient profit margins."

About macrolide antibiotics

Macrolide antibiotics prevent the bacterial growth by interfering with their protein synthesis, through binding to the bacterial ribosomal subunit 50S, thus subsequently inhibiting the translocation of peptides. Among the commonly used macrolides, azithromycin accounted for more than 50% of the China's macrolide market. Azithromycin is an effective and well tolerated in the treatment of respiratory tract, skin and soft tissue infections in children. Pathogens susceptible to azithromycin include Haemophilus influenzae (including ampicillin-resistant strains), Moraxella catarrhalis, Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella spp., Streptococcus pyogenes and Streptococcus agalactiae. Azithromycin is administered once daily, achieves clinically relevant concentrations at sites of infection, and has few drug interactions (Langtry and Balfour Drugs. 1998 Aug 56(2):273-97. Azithromycin. A review of its use in paediatric infectious diseases). Tianyin's Azithromycin Dispersible Tablets were included in China's essential drug list (EDL), and have enjoyed more than 60% annual revenue growth since its market debut in 2008.

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading pharmaceutical company that specializes in the development, manufacturing, marketing and sale of patented medicine, modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of- the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective national medical insurance program, 7 are included in the essential drug list of China. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. Tianyin currently is in the process of completing its Jiangchuan macrolide facility construction. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong, M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Web:   http://www.tianyinpharma.com
     Email: [email protected]
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +86-134-36-550011 (China)
            +1-949-350-6999 (U.S.)
     Add:   23rd Floor Unionsun Yangkuo Plaza
            No 2 Block 3 South Renmin Road
            Chengdu, 610041
            China

SOURCE Tianyin Pharmaceutical Co., Inc.